Experience the thrill of venturing into uncharted territories with CarthaGeneticsยฎ, a trailblazing consulting firm dedicated to transforming the landscape of rare diseases, advanced therapies, and orphan drugs. Founded in 2004 by the visionary Philippe Carteron, CarthaGeneticsยฎ is on a mission to revolutionize healthcare across Western Europe, Turkey, and North Africa. CarthaGeneticsยฎ has earned i
ts reputation as the go-to partner for the most prestigious biotech and pharma companies, including Cas Alexion, Alnylam, Amicus, Biogen, BioMarin, FoldRX/Pfizer, Genzyme, Horizon, Insmed, Orchard, PTC, RegenXbio, Shire, Ultragenyx, as well as for the Turkish Ministry of Health and Turkish Pharmacist Association (TEB). With an unwavering focus on innovative medicines, particularly in the realm of cell and gene therapies, CarthaGeneticsยฎ brings a wealth of expertise to the table.
๐ผ๐๐๐๐ก๐๐ง๐๐ฉ๐๐ฃ๐ ๐ฎ๐ค๐ช๐ง ๐๐ก๐๐ฃ๐๐๐๐ก ๐ฉ๐ง๐๐๐ก ๐๐ฃ๐ง๐ค๐ก๐ก๐ข๐๐ฃ๐ฉ
Imagine the exhilaration of accelerating the pace of clinical trials. CarthaGeneticsยฎ excels in patient identification and collaboration with your Contract Research Organizations (CROs), significantly speeding up enrollment. With a strong network in various countries, encompassing renowned medical professionals specializing in various fields, from pediatricians to geneticists, CarthaGeneticsยฎ is poised to revolutionize the research landscape.
๐๐๐ค๐ฃ๐๐๐ง๐๐ฃ๐ ๐๐๐ง๐ก๐ฎ ๐ผ๐๐๐๐จ๐จ ๐๐ง๐ค๐๐ง๐๐ข๐จ
Embark on an extraordinary journey of compassion and hope with CarthaGeneticsยฎ's Early Access Programs. In countries where such programs are permitted, CarthaGeneticsยฎ facilitates compassionate use and named patient sales, providing a lifeline to those in need. From France's Accรจs Prรฉcoce to Italy's Law 648/Law 326 and Turkey's Endikasyon Dฤฑลฤฑ Kullanฤฑm Kฤฑlavuzu, CarthaGeneticsยฎ empowers patients and healthcare providers alike.
๐๐ญ๐ฅ๐๐ฃ๐๐๐ฃ๐ ๐๐ค๐ง๐๐ฏ๐ค๐ฃ๐จ ๐ฌ๐๐ฉ๐ ๐ฝ๐๐ค๐จ๐๐ข๐๐ก๐๐ง๐จ
Venture into new frontiers of healthcare with CarthaGeneticsยฎ's biosimilars of orphan drugs. In North Africa, where Orphan Drug exclusivity is absent, CarthaGeneticsยฎ is spearheading the development of affordable and accessible treatments. With a population of approximately 100 million, this represents a tremendous opportunity to make a lasting impact.
๐
๐ค๐๐ฃ ๐ฉ๐๐ ๐
๐ค๐ช๐ง๐ฃ๐๐ฎ
Ready to embark on an exhilarating adventure in healthcare? Whether you have questions, want to explore collaboration possibilities, or simply seek more information, reach out to us at [email protected] or call our Swiss headquarter at +41 22 575 31 31. Discover more about our groundbreaking work at www.carthagenetics.com. Together, we can redefine the future of rare disease treatment.
